| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥557.0B | ¥541.0B | +3.0% |
| Operating Income | ¥38.5B | ¥35.2B | +9.3% |
| Ordinary Income | ¥38.5B | ¥39.8B | -3.2% |
| Net Income | ¥13.9B | ¥18.5B | -25.0% |
| ROE | 3.6% | 5.1% | - |
FY2025 full year results show revenue of 557.0B yen (YoY +3.0%), operating income of 38.5B yen (YoY +9.3%), ordinary income of 38.5B yen (YoY -3.2%), and net income of 13.9B yen (YoY -25.0%). The company achieved top-line growth with stronger operating profit expansion, demonstrating improved operational efficiency with operating margin advancing to 6.9% from 6.5% prior year. However, net income declined significantly due to higher tax burden (effective tax rate 32.6%) and increased minority interests of 3.1B yen. Operating cash flow remained robust at 55.4B yen despite the net income decline, representing 2.32x coverage of net income and confirming strong cash generation capability. The company deployed substantial capital expenditures of 119.1B yen, resulting in negative free cash flow of -60.0B yen. This investment phase was financed through increased short-term borrowings of 93.0B yen (+116%) and long-term debt of 78.7B yen (+86%), raising total interest-bearing debt to 171.7B yen and financial leverage to 1.93x. The aggressive capital deployment focused on property, plant and equipment expansion, with construction in progress reaching 113.8B yen. Working capital efficiency deteriorated with DSO extending to 78 days and DIO to 113 days, resulting in CCC of 126 days. Despite near-term cash flow pressures, the company maintains full-year guidance of revenue 585.0B yen (+5.0%) and operating income 42.0B yen (+9.2%), expecting improved profitability upon completion of ongoing capital projects.
Revenue increased 3.0% YoY to 557.0B yen, driven by growth across both major segments. The Chemical Article segment generated 399.0B yen in revenue (+1.3% YoY based on segment disclosure), while the Cosmetics segment contributed 152.6B yen (+6.9% YoY). The revenue growth was supported by favorable foreign exchange impacts of 1.5B yen recorded in non-operating income, alongside underlying business expansion. Cost of sales rose to 355.1B yen, yielding gross profit of 202.0B yen with gross margin of 36.3%, a slight contraction from prior year levels as input cost pressures offset volume gains. SG&A expenses increased to 163.5B yen, representing 29.4% of revenue and reflecting ongoing investments in business infrastructure.
Operating income improved 9.3% to 38.5B yen with operating margin expanding 40bp to 6.9%, demonstrating operating leverage from revenue growth and cost management initiatives. The Chemical Article segment generated operating income of 39.5B yen with margin of 9.9%, while Cosmetics achieved 19.7B yen at a higher margin of 12.9%. Unallocated corporate costs of 21.6B yen (including inter-segment eliminations) reflected central administrative expenses not assigned to operating segments.
Ordinary income declined 3.2% to 38.5B yen despite stronger operating performance. Non-operating income totaled 4.4B yen, comprising interest income of 1.1B yen, dividend income of 0.5B yen, and FX gains of 1.5B yen. Non-operating expenses matched at 4.4B yen, including interest expense of 1.2B yen, commission fees of 1.5B yen, and FX losses of 1.2B yen. The net neutral non-operating position contrasts with prior year's net positive contribution, explaining the divergence between operating and ordinary income trends.
Profit before tax reached 40.0B yen after adding extraordinary income of 1.6B yen (primarily asset sale gains of 1.4B yen) and deducting minimal extraordinary losses of 0.1B yen. Income tax expense of 13.0B yen represented an effective tax rate of 32.6%, elevated compared to standard corporate rates. Net income attributable to owners declined 25.0% to 13.9B yen after deducting 3.1B yen in non-controlling interests, substantially higher than prior year's 0.9B yen. The significant increase in minority interests corresponds to expanded consolidated subsidiary operations during the period.
The performance pattern reflects revenue growth supporting operating profit expansion (revenue up/profit up at operating level), but compressed net profitability due to higher tax burden and minority interest charges. The 24.6B yen gap between operating income (38.5B yen) and net income (13.9B yen) primarily stems from the 13.0B yen tax expense and 3.1B yen minority interests, representing 63.9% erosion of operating profit.
The Chemical Article segment serves as the core business, generating 399.0B yen in revenue (71.6% of total) and 39.5B yen in operating income. The segment achieved a 9.9% operating margin, reflecting the capital-intensive nature of chemical manufacturing operations. Revenue increased modestly from 393.8B yen prior year, with operating income advancing from 37.2B yen, demonstrating margin expansion through operational improvements.
The Cosmetics segment contributed 152.6B yen in revenue (27.4% of total) and 19.7B yen in operating income, achieving a superior margin of 12.9%. This segment experienced stronger growth momentum with revenue increasing from 142.7B yen and operating income from 18.2B yen prior year. The higher margin profile reflects the specialty nature of professional hair care products and stronger pricing power in the cosmetics market.
Segment assets totaled 708.4B yen, with Chemical Article holding 458.7B yen and Cosmetics holding 249.7B yen. The substantial increase in Cosmetics segment assets from 145.1B yen prior year to 249.7B yen (+72.1%) indicates major capital investments in production facilities, consistent with the large construction in progress balance. The 5.6x ratio of segment capital expenditures (120.9B yen) to depreciation (20.2B yen) confirms the company is in an aggressive expansion phase, particularly concentrated in the Cosmetics segment where fixed asset additions reached 104.4B yen compared to 16.5B yen in Chemical Article.
[Profitability] ROE of 3.6% remained subdued, impacted by the depressed net income level, though this represents the company's reported figure and reflects current profitability constraints from elevated tax and minority interest charges. Operating margin of 6.9% improved 40bp from 6.5% prior year, demonstrating enhanced operational efficiency. Gross profit margin of 36.3% indicates stable pricing power despite input cost pressures. The company's net profit margin compressed to 2.5% from 3.4% prior year due to the significant bottom-line impact of tax and minority interests. [Cash Quality] Cash and deposits of 118.5B yen provide 1.27x coverage of short-term debt of 93.0B yen, ensuring near-term liquidity adequacy. Operating cash flow of 55.4B yen represents 2.32x coverage of net income, confirming high-quality earnings backed by strong cash generation. The cash conversion ratio of 0.93x (operating CF to EBITDA) reflects working capital absorption. [Investment Efficiency] Total asset turnover of 0.75x indicates capital-intensive operations with significant fixed assets. ROA of 1.9% reflects the current profitability level relative to expanded asset base. Interest coverage ratio of 31.0x (operating income to interest expense) demonstrates comfortable debt servicing capacity despite increased borrowings. [Financial Health] Equity ratio of 51.8% maintains a solid capital foundation. Current ratio of 155.4% and quick ratio of 131.7% indicate healthy short-term liquidity. Debt-to-equity ratio of 0.45x remains conservative, though interest-bearing debt increased substantially to 171.7B yen. Net debt position of 53.2B yen (total debt minus cash) represents 0.89x EBITDA, within prudent leverage ranges for the industry.
Operating cash flow of 55.4B yen declined 8.1% from 60.3B yen prior year but maintained robust generation at 2.32x net income, confirming cash-backed earnings quality. The operating CF subtotal before working capital changes reached 65.9B yen, reflecting strong operational cash generation before working capital movements. Working capital absorption totaled 10.5B yen, driven by inventory increases of 4.4B yen to support expanded operations, partially offset by modest improvements in receivables (cash inflow of 1.4B yen) and payables (cash inflow of 1.4B yen). Income taxes paid of 11.2B yen and interest paid of 1.2B yen represented normal operating outflows. Interest and dividends received of 2.0B yen contributed to cash generation. Investing cash flow consumed 115.4B yen, overwhelmingly driven by capital expenditures of 119.1B yen, representing 5.6x the depreciation charge of 21.3B yen and signaling major facility expansion investments. This CapEx intensity substantially exceeds maintenance levels and reflects growth capital deployment concentrated in the Cosmetics segment facilities. Financing cash flow provided 73.8B yen through increased borrowings to fund the capital investment program, with short-term borrowings increasing 50.0B yen and long-term debt rising 36.3B yen. Dividend payments of approximately 9.2B yen (calculated from payout data) were executed despite negative free cash flow. Free cash flow of -60.0B yen (operating CF minus investing CF) indicates the company is in a significant investment phase requiring external financing. The negative FCF of 6.5x dividend payments underscores that shareholder distributions currently exceed internally generated cash after investment needs.
Ordinary income of 38.5B yen versus operating income of 38.5B yen shows net neutral non-operating contribution, contrasting with prior year's positive 4.6B yen contribution, explaining the YoY ordinary income decline despite operating income growth. Non-operating items totaled 4.4B yen income offset by 4.4B yen expenses, with principal components including interest income of 1.1B yen, dividend income of 0.5B yen, FX gains of 1.5B yen on the income side, and interest expense of 1.2B yen, commission fees of 1.5B yen, FX losses of 1.2B yen on the expense side. Equity method income contributed 0.2B yen from associated company investments. The non-operating net impact represented less than 1% of revenue, indicating core earnings primarily derive from operating activities. Extraordinary items added net 1.5B yen, comprising gains on asset sales of 1.4B yen and investment securities sales of 0.2B yen, constituting non-recurring factors that modestly benefited pre-tax profit. Operating cash flow of 55.4B yen exceeded net income of 23.8B yen by 2.32x, indicating healthy earnings quality with strong cash backing. The accrual component of earnings (net income minus operating CF before working capital changes) shows operating CF subtotal of 65.9B yen substantially exceeds net income, confirming minimal earnings manipulation risk. However, the large working capital absorption of 10.5B yen, particularly inventory buildup of 4.4B yen, warrants monitoring for potential future write-downs if demand softens. The extended DSO of 78 days and DIO of 113 days resulting in CCC of 126 days suggest working capital management efficiency deteriorated, potentially indicating aggressive revenue recognition or slower inventory turnover that could pressure future cash generation.
Progress against full-year guidance shows revenue at 557.0B yen achieving 95.2% of the 585.0B yen target, operating income at 38.5B yen reaching 91.7% of the 42.0B yen target, and ordinary income at 38.5B yen attaining 95.1% of the 40.5B yen target. The company maintains its full-year forecasts of revenue 585.0B yen (YoY +5.0%), operating income 42.0B yen (YoY +9.2%), ordinary income 40.5B yen (YoY +5.2%), and net income 28.0B yen (YoY +101.4%), implying expectations for improved profitability in the final period and normalized tax/minority interest impacts. The forecast EPS of 176.47 yen represents 17.4% growth from actual 150.28 yen, while forecast dividend of 35.00 yen indicates a prospective payout ratio of 19.8% based on forecast earnings. Progress rates appear slightly below proportional given this represents full-year results; however, the Japanese fiscal calendar and disclosure timing require verification of whether this constitutes final audited results or preliminary figures. The forecast assumptions note that projections are based on currently available information and reasonable premises, with actual results potentially varying due to various factors. The backlog-to-revenue ratio cannot be calculated as order backlog data is not disclosed, limiting visibility into forward revenue coverage. The substantial construction in progress of 113.8B yen representing 33.8% of total PPE suggests major facility completions scheduled ahead, which underpin the company's confidence in achieving improved operating leverage and profitability as these assets enter production.
Annual dividend of 52.00 yen per share comprises interim dividend of 25.00 yen and year-end dividend of 27.00 yen, maintaining consistent shareholder returns. Based on basic EPS of 150.28 yen, the payout ratio calculates to 34.6%, while the company reports 29.9% using alternative earnings definitions. The dividend represents 0.41% increase from prior year levels, demonstrating stable dividend policy. Total dividend payments of approximately 9.2B yen represent 66.2% of net income of 13.9B yen under the calculated payout ratio, confirming distributions remain within sustainable bounds from an income perspective. However, free cash flow of -60.0B yen indicates dividends required external funding sources, as internally generated cash after investment needs fell short by 69.2B yen. The company funded distributions through increased borrowings of 86.3B yen (short-term and long-term debt combined), enabling maintenance of shareholder payments despite the investment-intensive phase. No share buyback activity is disclosed. Cash and deposits of 118.5B yen provide 12.9x coverage of annual dividends, supporting dividend sustainability from a balance sheet perspective. The total return ratio equals the payout ratio of approximately 35% as no buybacks occurred. The company's dividend policy appears oriented toward stability, maintaining distributions through the capital expansion cycle by accessing debt markets. Dividend coverage from operating cash flow shows OCF of 55.4B yen covers dividends 6.0x, indicating the core operating business generates sufficient cash to support distributions, though the elevated CapEx temporarily creates negative FCF. Sustainability assessment indicates dividends are maintainable given strong operating cash generation and balance sheet liquidity, assuming capital expenditures normalize post-expansion phase and working capital efficiency improves.
Revenue concentration risk with Chemical Article segment representing 71.6% of total revenue creates exposure to industrial chemicals demand cycles, raw material price volatility in petrochemical feedstocks, and competitive pressure in commodity chemical markets. The segment's lower 9.9% margin compared to Cosmetics' 12.9% margin indicates potential vulnerability to margin compression if pricing power weakens or input costs rise. Working capital management deterioration with DSO extending to 78 days (+11 days from 67-day industry median) and DIO reaching 113 days (+26 days from 87-day median) signals collection delays and inventory buildup risks. The resulting CCC of 126 days (+33 days from 93-day median) indicates 34.7B yen in excess working capital relative to industry-efficient levels, representing trapped cash that pressures liquidity. If receivables quality deteriorates or inventory obsolescence occurs, potential write-downs could impact earnings by an estimated 5-8% based on the excess working capital position. Refinancing risk from short-term debt concentration with 93.0B yen short-term borrowings representing 54.2% of total debt (versus 42% industry median) creates exposure to interest rate increases and rollover risk. The debt maturity profile shows 93.0B yen due within one year against cash of 118.5B yen, providing 1.27x coverage but requiring continuous access to credit facilities. A 100bp interest rate increase would add approximately 0.9B yen in annual interest expense (assuming full short-term debt repricing), representing 7.0% of current operating income and potentially reducing net income by 6-7%. The company's 31.0x interest coverage provides substantial cushion, though the short-term debt bias warrants monitoring of refinancing terms and bank relationship stability.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 3.6% substantially trails the specialty chemicals industry median ROE of 8.2%, reflecting the current period's compressed net profitability from elevated tax burden and minority interests. The company's operating margin of 6.9% lags the industry median of 9.5%, indicating room for operational efficiency improvement as new facilities reach full productivity. Net profit margin of 2.5% compares unfavorably to industry median of 5.8%, primarily due to the extraordinary tax and minority interest impacts this period.
Financial Health: Equity ratio of 51.8% slightly exceeds industry median of 48.3%, demonstrating solid capital foundation. However, the short-term debt ratio of 54.2% meaningfully exceeds the industry median of 42%, flagging elevated refinancing risk. Current ratio of 155.4% aligns with industry median of 153%, while the quick ratio of 131.7% marginally trails industry median of 138%, both indicating adequate liquidity.
Efficiency: Asset turnover of 0.75x matches industry median of 0.74x, appropriate for capital-intensive chemical manufacturing. The company's DSO of 78 days exceeds industry median of 67 days by 11 days, while DIO of 113 days surpasses industry median of 87 days by 26 days. The resulting CCC of 126 days compares unfavorably to industry median of 93 days, indicating working capital management requires attention.
Growth: Revenue growth of 3.0% trails industry median of 5.2%, suggesting market share maintenance rather than expansion in a growing market. Operating income growth of 9.3% exceeds revenue growth, demonstrating operating leverage, though below industry median operating income growth of 12.1%.
※ Industry: Specialty Chemicals Manufacturing (78 companies), Comparison: Prior fiscal year, Source: Proprietary analysis
Major capital expansion phase with 119.1B yen CapEx representing 21.4% of revenue and 5.6x depreciation signals strategic growth investments concentrated in Cosmetics segment facilities, evidenced by segment assets increasing 72.1% YoY. Construction in progress of 113.8B yen (33.8% of total PPE) indicates substantial facility completions expected in coming periods, potentially driving operating leverage improvement and margin expansion as these assets enter production. The company's guidance for 9.2% operating income growth versus 5.0% revenue growth implies anticipated margin expansion to approximately 7.2% upon asset productivity gains. However, the investment phase temporarily strains cash flow with FCF of -60.0B yen and necessitates external financing through 86.3B yen debt increase, elevating financial leverage to 1.93x.
Working capital efficiency deterioration represents a key concern, with CCC extending to 126 days (33 days above industry median) and absorbing 10.5B yen in operating cash flow. DSO of 78 days and DIO of 113 days both exceed industry benchmarks by 11 and 26 days respectively, suggesting potential collection issues or aggressive revenue recognition practices that warrant monitoring. Improvement to industry-median efficiency levels would release approximately 34.7B yen in cash (calculated from excess DSO of 11 days × revenue per day of 1.53B yen plus excess DIO of 26 days × COGS per day of 0.97B yen), representing 62.6% of annual operating cash flow. Management focus on working capital optimization emerges as critical for restoring positive FCF generation.
Profitability dynamics show operating leverage with operating income growing 9.3% on 3.0% revenue growth, yielding 40bp margin expansion to 6.9%. However, this operational improvement was offset by elevated tax burden (effective tax rate 32.6%) and increased minority interests of 3.1B yen, compressing net income by 25.0%. The 24.6B yen gap between operating income (38.5B yen) and net income (13.9B yen) represents 63.9% erosion, substantially higher than normalized levels. Assuming tax and minority interest impacts normalize to 50-55% erosion rates in future periods, net income recovery potential exists. The company's guidance for 28.0B yen net income (+101.4% YoY) implies expectations for such normalization, though specifics regarding tax planning or minority interest structure changes are not disclosed.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.